Cohance Lifesciences Limited has informed the Exchange regarding 'Disclosure under the SEBI (Prohibition of Insider Trading) Regulations, 2015'.
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. V Prasada Raju, Managing Director of Cohance Lifesciences, sold 6,00,000 shares of the company on August 26, 2025, through on-market trades on NSE/BSE for a total value of approximately Rs. 52.82 Crores. Following this sale, his personal shareholding reduced from 7,13,259 shares (0.19%) to 1,13,259 shares (0.03%) of the company. The MD stated the sale was primarily to repay a loan availed for exercising stock options under the company's ESOP scheme along with the associated tax obligations, and additionally to discharge certain personal liabilities. The Managing Director also reaffirmed his commitment to the company's strategic vision of becoming a leading technology-led CDMO with a global footprint. This disclosure was made under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015.
The sale represents a small reduction of about 0.16 percentage points in the MD's personal stake, and the reasons (ESOP loan repayment and personal obligations) are clearly disclosed, which is likely to be viewed neutrally by the market. Shareholders may note the reduced personal holding of the MD, but this is not a significant enough transaction to materially affect stock price or promoter control.